Evaluating TKI Efficacy and Safety in HER2-Mutant NSCLC from SOHO-01 Trial

EP: 1.Value of Comprehensive Molecular Testing in NSCLC

EP: 2.Unmet Needs in HER2-Mutant NSCLC

EP: 3.Treatment of HER2-Mutant NSCLC: Consequences of Delays and Strategies to Improve Timely Initiation

EP: 4.Overview of HER2-Targeted Therapies in NSCLC

EP: 5.Mechanistic Role of Emerging Tyrosine Kinase Inhibitors (TKIs) in HER2-Mutant NSCLC

EP: 6.Efficacy and Safety of Zongertinib in Previously Treated and Treatment-Naïve HER2-Mutant NSCLC from Beamion LUNG-1 Trial

Now Viewing

EP: 7.Evaluating TKI Efficacy and Safety in HER2-Mutant NSCLC from SOHO-01 Trial

EP: 8.Safety Considerations and Patient-Reported Outcomes of TKIs in HER2-Mutant NSCLC

This episode focuses on the SOHO-01 trial data for sevabertinib in HER2-mutant non-small cell lung cancer (NSCLC). The discussion highlights that sevabertinib, an emerging tyrosine kinase inhibitor, demonstrated strong clinical activity in both previously treated and treatment-naive patient populations. In the SOHO-01 trial, response rates exceeded 70% among those who had not received prior systemic therapy, indicating significant efficacy as a potential first-line option. Substantial responses were also observed in pretreated cohorts. The safety profile of sevabertinib was described as favorable and tolerable, supporting its use in clinical practice. The panel notes that these promising results suggest sevabertinib could play an important role for patients with HER2-mutant NSCLC, but acknowledges that ongoing and future studies, such as the SOHO-02 trial, will be necessary to confirm its effectiveness and define its placement in the treatment landscape.